BACKGROUND: Studies of pediatric intensive care unit (PICU) patients have shown a significant association of morbidity and mortality with hyperglycemia. We retrospectively evaluated the degree of hyperglycemia as well as its correlation with glucocorticoid and insulin use and assessed its association with hospital length of stay (LOS) and mortality. This study preceded the initiation of a standard glycemic control protocol. METHODS: We examined medical records at Kosair Children's Hospital for all PICU admissions from 2008 of patients without diabetes mellitus. Critical illness hyperglycemia (CIH) was defined by having three or more peak glucose values greater than thresholds of 110, 140, 180, and 200 mg/dl. These patients were evaluated for glucocorticoid, insulin use, and outcome measures. RESULTS: We evaluated the eligible 1173 admissions, where 10.5% of these patients reached the highest threshold (200 mg/dl) of CIH. Glucocorticoids were used in 43% of these patients, with dexamethasone being the most common (58%). There was a significant correlation between glucocorticoids and higher peak glucose values, where 81% of the patients who were above the 200 mg/dl cutoff level were treated with glucocorticoids. Only 36.8% in that group were also treated with insulin. Patients at the 200 mg/dl cutoff had the highest median PICU and total hospital length of stays (4 and 10 days, respectfully). Mortality was associated with increasing glucose levels, reaching 18.7% among patients above the 200 mg/dl cutoff. CONCLUSION: Hyperglycemia was prevalent in the PICU and was associated with increased morbidity, as characterized by increased LOS and increased mortality. Glucocorticoid use was prevalent among patients exhibiting hyperglycemia. Insulin use was uncommon.
BACKGROUND: Studies of pediatric intensive care unit (PICU) patients have shown a significant association of morbidity and mortality with hyperglycemia. We retrospectively evaluated the degree of hyperglycemia as well as its correlation with glucocorticoid and insulin use and assessed its association with hospital length of stay (LOS) and mortality. This study preceded the initiation of a standard glycemic control protocol. METHODS: We examined medical records at Kosair Children's Hospital for all PICU admissions from 2008 of patients without diabetes mellitus. Critical illness hyperglycemia (CIH) was defined by having three or more peak glucose values greater than thresholds of 110, 140, 180, and 200 mg/dl. These patients were evaluated for glucocorticoid, insulin use, and outcome measures. RESULTS: We evaluated the eligible 1173 admissions, where 10.5% of these patients reached the highest threshold (200 mg/dl) of CIH. Glucocorticoids were used in 43% of these patients, with dexamethasone being the most common (58%). There was a significant correlation between glucocorticoids and higher peak glucose values, where 81% of the patients who were above the 200 mg/dl cutoff level were treated with glucocorticoids. Only 36.8% in that group were also treated with insulin. Patients at the 200 mg/dl cutoff had the highest median PICU and total hospital length of stays (4 and 10 days, respectfully). Mortality was associated with increasing glucose levels, reaching 18.7% among patients above the 200 mg/dl cutoff. CONCLUSION:Hyperglycemia was prevalent in the PICU and was associated with increased morbidity, as characterized by increased LOS and increased mortality. Glucocorticoid use was prevalent among patients exhibiting hyperglycemia. Insulin use was uncommon.
Authors: Daniël H van Raalte; Valentina Nofrate; Mathijs C Bunck; Thijs van Iersel; Jeroen Elassaiss Schaap; Ulla K Nässander; Robert J Heine; Andrea Mari; Wim H A Dokter; Michaela Diamant Journal: Eur J Endocrinol Date: 2010-02-02 Impact factor: 6.664
Authors: Jennifer J Verhoeven; Jeannette B Brand; Mirjam M van de Polder; Koen F M Joosten Journal: Pediatr Crit Care Med Date: 2009-11 Impact factor: 3.624
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: A Chiaretti; R De Benedictis; A Langer; C Di Rocco; C Bizzarri; A Iannelli; G Polidori Journal: Childs Nerv Syst Date: 1998-09 Impact factor: 1.475
Authors: Yaseen M Arabi; Ousama C Dabbagh; Hani M Tamim; Abdullah A Al-Shimemeri; Ziad A Memish; Samir H Haddad; Sofia J Syed; Hema R Giridhar; Asgar H Rishu; Mouhamad O Al-Daker; Salim H Kahoul; Riette J Britts; Maram H Sakkijha Journal: Crit Care Med Date: 2008-12 Impact factor: 7.598
Authors: Vijay Srinivasan; Philip C Spinella; Henry R Drott; Carey L Roth; Mark A Helfaer; Vinay Nadkarni Journal: Pediatr Crit Care Med Date: 2004-07 Impact factor: 3.624
Authors: Angelo Polito; Ravi R Thiagarajan; Peter C Laussen; Kimberlee Gauvreau; Michael S D Agus; Mark A Scheurer; Frank A Pigula; John M Costello Journal: Circulation Date: 2008-11-10 Impact factor: 29.690
Authors: Luis Miguel Toro-Polo; Ricardo Yannick Ortiz-Lozada; Silvana Lucia Chang-Grozo; Adrian V Hernandez; Raffo Escalante-Kanashiro; Lely Solari-Zerpa Journal: Rev Bras Ter Intensiva Date: 2018 Oct-Dec